Universal reference book for medicines
Product name: UROFIN (UROFIN)

Active substance: finasteride

Type: The drug for the treatment of benign prostatic hyperplasia.
Inhibitor of 5? -reductase
Manufacturer: ACTAVIS GROUP PTC ehf.
(Iceland) manufactured by INTAS PHARMACEUTICALS (India)
Description of the active substance:
This information is a reference and it is not enough that the drug has been prescribed by a doctor ..

The inhibitor of 5-alpha reductase is an enzyme that converts testosterone into a more active dihydrotestosterone.
Reduces the content of dihydrotestosterone in the blood and tissues of the prostate gland. Oppressing the stimulating effect of dihydrotestosterone on the development of prostatic adenoma.
Finasteride helps reduce the size of the enlarged gland, improves urine flow and reduces symptoms associated with benign prostatic hypertrophy.
To reduce the clinical manifestations of the disease may take several months of treatment.
Well absorbed and penetrates into the tissues and body fluids, is found in the ejaculate.
Bioavailability is 80% and does not depend on food intake. C max is achieved in 1-2 hours. Communication with plasma proteins is 90%. It is excreted as metabolites by the kidneys (39%) and through the intestine (57%). T 1/2 - 6-8 hours. Long-term (3-7 months) reception at a dose of 5 mg / day reduces the concentration of serum 5-alpha-dihydrotestosterone by 70%.
Benign prostatic hyperplasia (to reduce prostate size, improve urine flow and reduce symptoms associated with hyperplasia, reduce the risk of acute urinary retention requiring catheterization or surgery, including transurethral resection of the prostate and prostatectomy).

The daily dose is 5 mg, the frequency of administration is 1 time / day.
Treatment is long.
On the part of the reproductive system: rarely - impotence, decreased libido, decreased ejaculate volume, gynecomastia.

Allergic reactions: skin rash, angioedema.

Hypersensitivity to finasteride, obstructive uropathy, prostate cancer.
Finasteride is not used in women and children.
Women of childbearing age and pregnant women should avoid contact with the drug, tk.
it has teratogenic properties (the ability to suppress the conversion of testosterone to dihydrotestosterone can cause impaired development of the genital organs in the male fetus), penetrates into the seminal fluid.
With caution appoint finasteride with hepatic insufficiency.

The drug is not used in children.

With caution appoint finasteride with hepatic insufficiency.

With a large volume of residual urine and / or a sharply reduced urine flow, one must keep in mind the development of obstructive uropathy.

Before the beginning of treatment with finasteride and periodically during the treatment should be carried out rectal examination, as well as research by other methods for the presence of prostate cancer.

There was no clinically significant interaction of finasteride with propranolol, digoxin, glyburide, warfarin, theophylline and antipyrin.

It seems that finasteride does not significantly affect the enzymatic system of cytochrome P450 and, accordingly, does not affect the pharmacokinetic indices of drugs metabolized by microsomal liver enzymes.

When concurrent use of finasteride with ACE inhibitors, alpha-adrenoblockers, beta-blockers, calcium channel blockers, nitrates, diuretics, histamine H2 blockers, HMG-CoA reductase inhibitors, NSAIDs, quinolones and benzodiazepines, no clinically significant drug interaction was observed.

Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y

Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!